 |
 |
|
|
|
RESÚMENES JUNIO 2010 |
Antipsicóticos
(Haga un click en la
información del journal
para acceder al resúmen)
5
– doble-ciego o
metanálisis; 4 – subanálisis o estudio
aleatorizado; 3
– revisión, abierto, básico; 2 –
casos; 1 – opinión
GRATIS = Texto
gratuito en algunos países de la región iberoamericana
5 - Efficacy of atypical v. typical antipsychotics in the
treatment of early psychosis: meta-analysis
Nicolas
A. Crossley, Miguel Constante, Philip McGuire, Paddy Power
The British Journal of Psychiatry (2010) 196: 434-439
4 - Risperidone Maintenance Treatment in Schizophrenia: A
Randomized, Controlled Trial
Chuan-Yue Wang, Yu-Tao
Xiang, Zhuo-Ji Cai, Yong-Zhen Weng, Qi-Jing Bo, Jing-Ping Zhao, Tie-Qiao Liu,
Gao-Hua Wang, Shi-Min Weng, Hong-Yan Zhang, Da-Fang Chen, Wai-Kwong Tang, and
Gabor S. Ungvari, For the Risperidone Maintenance Treatment in Schizophrenia
(RMTS) investigators
Am J
Psychiatry 2010; 167:676-685
3 - What Is Causing the Reduced Drug-Placebo Difference
in Recent Schizophrenia Clinical Trials and What Can be Done About It?
Aaron S. Kemp, Nina R.
Schooler, Amir H. Kalali, Larry Alphs, Ravi Anand, George Awad, Michael
Davidson, Sanjay Dubé, Larry Ereshefsky, Georges Gharabawi, Andrew C. Leon,
Jean-Pierre Lepine, Steven G. Potkin and An Vermeulen
Schizophrenia Bulletin
2010 36(3):504-509
3< - Antipsychotic Therapy During Early and Late Pregnancy.
A Systematic Review
Salvatore Gentile
Schizophrenia Bulletin
2010 36(3):518-544
3 - Evaluating Early Preventive Antipsychotic and
Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse
Model of Schizophrenia
Urs Meyer, Erica Spoerri,
Benjamin K. Yee, Markus J. Schwarz and Joram Feldon
Schizophrenia Bulletin
2010 36(3):607-623
4 - Trajectories and Antecedents of Treatment Response
Over Time in Early-Episode Psychosis
Stephen Z. Levine and J.
Rabinowitz
Schizophrenia Bulletin
2010 36(3):624-632
3 - The
effect of antipsychotic medication on facial affect recognition in
schizophrenia: A review
Roelie J. Hempel, Judith Anna Dekker, Nico
J.M. van Beveren, Joke H.M. Tulen and Michiel W.
Hengeveld
Psychiatry Research. Volume 178, Issue 1, 30 June 2010, Pages
1-9
4 - Antipsychotic medication and social cue recognition in chronic
schizophrenia
David Leland
Roberts, David Lewis Penn, Patrick Corrigan, Ilya Lipkovich, Bruce Kinon and
Ryan Andrew Black
Psychiatry Research. Volume 178, Issue 1, 30 June 2010, Pages
46-50
3 - Determinants
of work outcome in neuroleptic-resistant schizophrenia and schizoaffective
disorder: Cognitive impairment and clozapine treatment
Yasuhiro Kaneda, Karuna Jayathilak and Herbert
Meltzer
Psychiatry Research. Volume 178, Issue 1, 30 June 2010, Pages
57-62
3 - Patient participation in antipsychotic drug choice decisions
Johannes Hamann,
Joachim Kruse, Florian S. Schmitz, Werner Kissling and Frank-Gerald Pajonk
Psychiatry Research. Volume 178, Issue 1, 30 June 2010, Pages
63-67
3! - Incidence and risk for neutropenia/agranulocytosis
among clozapine users: A retrospective cohort study
Chaveewan Ratanajamit
International Journal of
Psychiatry in Clinical Practice. June
2010, Vol. 14, No. 2, Pages 109-115
3 - The Role of Ondansetron in the Treatment of
Schizophrenia
Bennett AC,
Vila TM
Ann Pharmacother. 2010 Jun 1. [Epub
ahead of print]
3! - A Systematic Review of
Aripiprazole—Dose, Plasma Concentration, Receptor Occupancy, and Response:
Implications for Therapeutic Drug Monitoring
Anna Sparshatt, David Taylor, Maxine X. Patel,
and Shitij Kapur
GRATIS 3 - Abnormal laboratory values during the
acute and recovery phases in schizophrenic patients: a retrospective study
Takahiko Nagamine
Neuropsychiatric Disease and Treatment. 2010,
Volume 2010:6 Pages 281 - 288
GRATIS 2! -
Post-injection delirium/sedation syndrome in patients with schizophrenia
treated with olanzapine long-acting injection, II: investigations of mechanism
David P McDonnell, Holland C Detke, Richard F Bergstrom, Prajakti Kothare, Jason Johnson, Mary Stickelmeyer, Manuel
V Sanchez-Felix, Sebastian
Sorsaburu and Malcolm I Mitchell
3 - The Antipsychotics Olanzapine,
Risperidone, Clozapine, and Haloperidol Are D2-Selective Ex Vivo but Not In Vitro
Patrick N McCormick, Shitij Kapur, Ariel Graff-Guerrero,
Roger Raymond, José N Nobrega and Alan A Wilson
Neuropsychopharmacology (2010) 35, 1826–1835
GRATIS 3< -
The switch from conventional to atypical antipsychotic treatment should not be
based exclusively on the presence of cognitive deficits. A pilot study in
individuals with schizophrenia
Gabriel Selva-Vera, Vicent Balanza-Martinez,
Jose Salazar-Fraile, Jose Sanchez-Moreno, Anabel Martinez-Aran, Patricia Correa, Eduard Vieta and Rafael Tabares-Seisdedos
3 - Psychiatrists’ attitude towards and knowledge of
clozapine treatment
J. Nielsen, M. Dahm, H.
Lublin, D. Taylor
Journal of
Psychopharmacology, Vol. 24, No. 7, 965-971 (2010)
Alvin Liew, Swapna Verma,
Lye Yin Poon, Abdin Edimansyah, Mythily Subramaniam, Janhavi Vaingankar, Siow
Ann Chong
Journal of
Psychopharmacology, Vol. 24, No. 7, 973-980 (2010)
2 - The combined use of risperidone long-acting injection
and clozapine in patients with schizophrenia non-adherent to clozapine: a case
series
Se Hyun Kim, Dong Chung
Jung, Yong Min Ahn, Yong Sik Kim
Journal of
Psychopharmacology, Vol. 24, No. 7, 981-986 (2010)
3 - The combined use of risperidone long-acting injection
and clozapine in patients with schizophrenia non-adherent to clozapine: a case
series
Se Hyun Kim, Dong Chung
Jung, Yong Min Ahn, Yong Sik Kim
Journal of
Psychopharmacology, Vol. 24, No. 7, 981-986 (2010)
3 - Risperidone long-acting injection: factors associated
with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up
D. Taylor, V. Cornelius
Journal of
Psychopharmacology, Vol. 24, No. 7, 995-999 (2010)
4 - Comparison of metabolic and prolactin variables from
a six-month randomised trial of olanzapine and quetiapine in schizophrenia
C. Bushe, J. Sniadecki, AJ
Bradley, V. Poole Hoffmann
Journal of
Psychopharmacology, Vol. 24, No. 7, 1001-1009 (2010)
5 - A comparison of serum prolactin concentrations after
administration of paliperidone extended-release and risperidone tablets in
patients with schizophrenia
Joris Berwaerts, Adriaan
Cleton, Stefaan Rossenu, Krishna Talluri, Bart Remmerie, Luc Janssens, Sandra
Boom, Michelle Kramer, Mariëlle Eerdekens
Journal of
Psychopharmacology, Vol. 24, No. 7, 1011-1018 (2010)
4 - Evaluation of akathisia in patients with
schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc
analysis of pooled data from short- and long-term aripiprazole trials
John M Kane, Thomas RE
Barnes, Christoph U Correll, Gary Sachs, Peter Buckley, James Eudicone, Robert
McQuade, Quynh-Van Tran, Andrei Pikalov, III, Sheila Assunção-Talbott
Journal of
Psychopharmacology, Vol. 24, No. 7, 1019-1029 (2010)
3! - Incidence and persistence of tardive dyskinesia and
extrapyramidal symptoms in schizophrenia
DE Tenback, PN van Harten, CJ Slooff, J. van
Os
Journal of
Psychopharmacology, Vol. 24, No. 7, 1031-1035 (2010)
3! - Cognitive effects of antipsychotic dosage and
polypharmacy: a study with the BACS in patients with schizophrenia and
schizoaffective disorder
D. Élie, M. Poirier, JM
Chianetta, M. Durand, CA Grégoire, S. Grignon
Journal of
Psychopharmacology, Vol. 24, No. 7, 1037-1044 (2010)
3 - Avoidance-suppressing effect of antipsychotic drugs is
progressively potentiated after repeated administration: an interoceptive drug
state mechanism
A. Mead, M. Li
Journal of
Psychopharmacology, Vol. 24, No. 7, 1045-1053 (2010)
3 - The effect of risperidone on D-amino acid oxidase
activity as a hypothesis for a novel mechanism of action in the treatment of
schizophrenia
RM Abou El-Magd, HK Park,
T. Kawazoe, S. Iwana, K. Ono, SP Chung, M. Miyano, K. Yorita, T. Sakai, K.
Fukui
Journal of
Psychopharmacology, Vol. 24, No. 7, 1055-1067 (2010)
3 - Acute effects of olanzapine on behavioural expression
including the behavioural satiety sequence in female rats
GD Cooper, AJ Goudie, JCG
Halford
Journal of
Psychopharmacology, Vol. 24, No. 7, 1069-1078 (2010)
3 - Activation of the JAK-STAT pathway by olanzapine is
necessary for desensitization of serotonin2A receptor-stimulated phospholipase
C signaling in rat frontal cortex but not serotonin2A receptor-stimulated
hormone release
RK Singh, C. Jia, F. Garcia, GA Carrasco, G.
Battaglia, NA Muma
Journal of
Psychopharmacology, Vol. 24, No. 7, 1079-1088 (2010)
3 - Effect of lactational exposure of olanzapine on body
weight of mice: a comparative study on neonates of both the sexes during
post-natal development
AC Mishra, B. Mohanty
Journal of
Psychopharmacology, Vol. 24, No. 7, 1089-1096 (2010)
3 - Lactational exposure to atypical antipsychotic drugs
disrupts the pituitary-testicular axis in mice neonates during post-natal
development
Akash C Mishra, Banalata
Mohanty
Journal of
Psychopharmacology, Vol. 24, No. 7, 1097-1104 (2010)
3 - Olanzapine, not resperidone, exacerbates β-cell function and mass in ovariectomized diabetic rats and estrogen
replacement reverses them
Sunmin Park, Sang Mee Hong,
Il Sung Ahn, Sung Hoon Kim
Journal of
Psychopharmacology, Vol. 24, No. 7, 1105-1114 (2010)
3 - Relationship between response to risperidone, plasma
concentrations of risperidone and CYP3A4
polymorphisms in schizophrenia patients
J. Du, A. Zhang, L. Wang,
J. Xuan, L. Yu, R. Che, X. Li, N. Gu, Z. Lin, G. Feng, Q. Xing, L. He
Journal of
Psychopharmacology, Vol. 24, No. 7, 1115-1120 (2010)
3 - Safety evaluation of zotepine for the treatment of
schizophrenia
Michael Riedel
, Richard
Musil
Expert Opinion on Drug
Safety. July 2010, Vol. 9, No. 4,
Pages 659-666
3 - Potential
Complications of Combining Intramuscular Olanzapine with Benzodiazepines in
Emergency Department Patients
Michael P. Wilson, Kai MacDonald, Gary M.
Vilke and David Feifel
The
Journal of Emergency Medicine. Article in Press, June 2010
3 - Increase in brain-derived neurotrophic factor in first
episode psychotic patients after treatment with atypical antipsychotics
González-Pinto,
Ana; Mosquera, Fernando; Palomino, Aitor; Alberich, Susana; Gutiérrez, Arantza;
Haidar, Karim; Vega, Patricia; Barbeito, Sara; Ortiz, Agurtzane; Matute, Carlos
International
Clinical Psychopharmacology: July 2010 - Volume 25 - Issue 4 - pp 241-245
3 - Pharmacological Profile of Lurasidone, a Novel
Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and
5-HT1A Receptor Activity
Tadashi
Ishibashi, Tomoko
Horisawa, Kumiko
Tokuda, Takeo
Ishiyama, Masaaki
Ogasa, Rie
Tagashira, Kenji
Matsumoto, Hiroyuki
Nishikawa, Yoko Ueda, Satoko Toma, Hitomi Oki, Norihiko
Tanno, Ikutaro
Saji, Akira Ito, Yukihiro
Ohno
and Mitsutaka
Nakamura
JPET July 2010 vol.
334 no. 1 171-181
3! - Weight changes over time in adults treated with the
oral or depot formulations of olanzapine: a pooled analysis of 86 clinical
trials
Brian A Millen, Giedra M
Campbell, and Charles M Beasley
Journal of
Psychopharmacology. June 17, 2010
3! - Hyponatraemia as an Adverse Drug Reaction of
Antipsychotic Drugs: A Case-Control Study in VigiBase
Mannesse, Cyndie K.; van Puijenbroek, Eugène P.; Jansen, Paul A.F.; van
Marum, Rob J.; Souverein, Patrick C.; Egberts, Toine C.G
Drug
Safety: 1 July 2010 - Volume 33 - Issue 7 - pp 569-578
4 -
Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action:
Treatment Response Trajectories
Stephen Z. Levine and Stefan Leucht
Biological Psychiatry. Volume 68, Issue 1, 1 July 2010, Pages
86-92
3 - Combination Therapy in the Treatment of
Schizophrenia
C. Wolff-Menzler,
A. Hasan, B. Malchow, P. Falkai, T. Wobrock
Pharmacopsychiatry
2010; 43(4): 122-129
5 - Long-Term Assessment of Asenapine vs.
Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder
J. Schoemaker,
D. Naber, P. Vrijland, J. Panagides, R. Emsley
Pharmacopsychiatry
2010; 43(4): 138-146
5 - Pregnenolone and
Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and
Schizoaffective Disorder: An 8-Week, Double-Blind, Randomized, Controlled,
2-Center, Parallel-Group Trial
Michael S. Ritsner, Anatoly Gibel, Tatyana
Shleifer, Igor Boguslavsky, Ahmad Zayed, Rachel Maayan, Abraham Weizman, and
Vladimir Lerner
3 - The role of CYP2D6 and ABCB1
pharmacogenetics in drug-naïve patients with first-episode schizophrenia
treated with risperidone
Nikolina Jovanović,
Nada Božina, Mila Lovrić, Vesna Medved, Miro Jakovljević
and Alma Mihaljević Peleš
European Journal
of Clinical Pharmacology. June 2010
GRATIS 5 - A
randomised, double-blind, placebo-controlled trial of tropisetron in patients
with schizophrenia
Akihiro Shiina, Yukihiko Shirayama, Tomihisa
Niitsu, Tasuku Hashimoto,
Taisuke Yoshida, Tadashi Hasegawa, Tadashi Haraguchi, Nobuhisa Kanahara, Tetsuya Shiraishi, Mihisa Fujisaki, Goro Fukami, Michiko Nakazato, Masaomi
Iyo and Kenji Hashimoto
Annals of General Psychiatry 2010, 9:27
3! - Rates of Homicide During the First Episode of
Psychosis and After Treatment: A Systematic Review and Meta-analysis
Olav Nielssen and Matthew
Large
Schizophrenia Bulletin
2010 36(4):702-712
5 - Trimethoprim as Adjuvant Treatment in Schizophrenia:
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
Teshome Shibre, Atalay
Alem, Abdulreshid Abdulahi, Mesfin Araya, Teferra Beyero, Girmay Medhin,
Negusse Deyassa, Alemayehu Negash, Alemayehu Nigatu, Derege Kebede and Abebaw
Fekadu
Schizophrenia Bulletin
2010 36(4):846-851
3 - Chronic antipsychotic
treatment: protracted decreases in phospho-TrkA levels in the rat hippocampus
Alvin V. Terry Jr., Debra A. Gearhart, Anilkumar Pillai, Guodong Zhang
and Michael G. Bartlett
The International Journal of Neuropsychopharmacology
(2010), 13:799-805
3 - Effect of
hypertriglyceridemia on the pharmacokinetics and blood–brain barrier
penetration of clozapine and norclozapine following administration to rats
Pavel Gershkovich, Olena Sivak, Aishwariya
Sharma, Alasdair M. Barr, Ric Procyshyn and Kishor M. Wasan
European Neuropsychopharmacology. Volume 20, Issue 8,
August 2010, Pages 545-552
4 - Effect of
aripiprazole versus haloperidol on PANSS Prosocial items in early-episode
patients with schizophrenia
J.P. Docherty, R.A. Baker, J. Eudicone, S.
Mathew, R.N. Marcus, R.D. McQuade and R. Mankoski
Schizophrenia
Research. Volume 120, Issues 1-3, July 2010, Pages 199-203
5< - Short
term neurocognitive effects of treatment with ziprasidone and olanzapine in
recent onset schizophrenia
Nicoletta M.J. van Veelen, Koen. P. Grootens,
J. Peuskens, B.G.C. Sabbe, Miriam E. Salden, R.J. Verkes, René S. Kahn and
Margriet M. Sitskoorn
Schizophrenia
Research. Volume 120, Issues 1-3, July 2010, Pages 191-198
4 - Effects
of olanzapine and risperidone on lipid metabolism in chronic schizophrenic
patients with long-term antipsychotic treatment: A randomized five month study
Robert C. Smith, Jean-Pierre Lindenmayer,
Qiaoyan Hu, Erin Kelly, Thomas F. Viviano, James Cornwell, Sumathi
Vaidhyanathaswamy, Santica Marcovina and John M. Davis
Schizophrenia
Research. Volume 120, Issues 1-3, July 2010, Pages 204-209
3 - Long-Term Efficacy and Tolerability of
Clozapine Combined with Ziprasidone or Risperidone
A. Kuwilsky,
B. Krumm, S. Englisch, H. Dressing, M. Zink
3! - The Role of Ondansetron in the Treatment of
Schizophrenia
Allison C Bennett, Tania M
Vila
The Annals of Pharmacotherapy: Vol. 44, No. 7, pp.
1301-1306
3 - Antipsychotic Medication and
Oxidative Cell Stress: A Systematic Review
Peter Lepping, John Delieu, Richard Mellor,
John H. H. Williams, Peter R. Hudson, and Claire Hunter-Lavin
3! - Signal Detection and
Placebo Response in Schizophrenia: Parallels with Depression
Craig H.
Mallinckrodt, Lu Zhang, William R. Prucka, Brian A. Millen
Psychopharmacology Bulletin. 2010;43(1):53–72
| Regresar a RESÚMENES JUNIO 2010 |
©
1999-2010 Jorge M Tamayo, MD, BMSS
Creada en Enero 1999
| Declaración: El contenido de esta página web está basado en las revisiones de la literatura realizadas por el autor y las colaboraciones enviadas por los lectores. Este sitio de Internet está dirijido únicamente a profesionales de la salud en Iberoamérica. Si usted es residente de Estados Unidos de América o Europa, debe tener en cuenta que los contenidos no han sido escogidos con base en información aprobada por la FDA o la EMEA |